US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
CRYSTAL LAKE, Ill. - Aptar Pharma, a division of the $10.2 billion market cap AptarGroup (NYSE:ATR), announced Tuesday it has acquired the clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings, strengthening its early-phase drug development services.
The acquisition includes an FDA-inspected facility in Boonton, New Jersey, equipped with cGMP cleanrooms, high-potency API suites, biologics capabilities, and advanced fill-finish technologies that align with Aptar’s drug delivery solutions portfolio. According to InvestingPro data, AptarGroup maintains strong financial health with a solid 38% gross margin and moderate debt levels.
According to the company’s press release statement, the move addresses market demand for clinical trial material supply services, particularly for Phase 1 and 2 cGMP fill and finish services for orally inhaled nasal drug products (OINDPs).
"By integrating Phase 1 and 2 clinical manufacturing capabilities, we’re not just expanding our technical footprint - we’re deepening our commitment to customers seeking a seamless and accelerated path to market," said Gael Touya, President of Aptar Pharma.
The acquisition builds on a previous collaboration between the two companies and aims to accelerate adoption of new drug delivery technologies, initially focusing on OINDPs, with potential expansion into other delivery methods.
Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), which specializes in drug delivery, consumer product dispensing and active material science solutions.
Financial terms of the acquisition were not disclosed in the announcement. InvestingPro analysis shows AptarGroup has maintained dividend payments for 33 consecutive years, with recent dividend growth of nearly 10%. For detailed insights and more exclusive metrics, investors can access the comprehensive Pro Research Report, available to InvestingPro subscribers.
In other recent news, AptarGroup Inc. reported its first-quarter earnings for 2025, noting a modest earnings per share (EPS) beat but a decline in revenue compared to forecasts. The company’s adjusted EPS was $1.20, surpassing the expected $1.16, while revenue reached $887 million, falling short of the projected $929.07 million. Additionally, AptarGroup announced the expansion of its 2018 Equity Incentive Plan, increasing the number of shares available for issuance by 1,000,000 following stockholder approval. The company also declared a quarterly cash dividend of $0.45 per share, set to be paid in August 2025. In corporate governance developments, three directors were elected to serve until the 2028 Annual Meeting, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Analyst feedback from firms such as Bank of America and Baird focused on inventory destocking in the cold/cough market and strong demand for GLP-1 injectables. These recent developments highlight AptarGroup’s ongoing strategic initiatives and financial performance amidst challenging market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.